ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5

Wang, Yanqun; Yan, An; Song, Deyong; Dong, Chuangchuang; Rao, Muding; Gao, Yuanzhu; Qi, Ruxi; Ma, Xiaomin; Wang, Qiaoping; Xu, Hongguang; Liu, Hong; Han, Jing; Duan, Maoqin; Liu, Shuo; Yu, Xiaoping; Zong, Mengqi; Feng, Jianxia; Jiao, Jie; Zhang, Huimin; Li, Min; Yu, Beibei; Wang, Yanxia; Meng, Fanhao; Ni, Xiaodan; Li, Ying; Shen, Zhenduo; Sun, Baiping; Shao, Xin; Zhao, Haifeng; Zhao, Yanyan; Li, Rui; Zhang, Yanan; Du, Guangying; Lu, Jun; You, Chunna; Jiang, Hua; Zhang, Lu; Wang, Lan*广州医学院; 1
Cell Discovery2023-1-7DOI: 10.1038/s41421-022-00509-9
7被引14阅读
引用收藏
分享

摘要

SARS-CoV-2 Omicron subvariants have demonstrated extensive evasion from monoclonal antibodies (mAbs) developed for clinical use, which raises an urgent need to develop new broad-spectrum mAbs. Here, we report the isolation and analysis of two anti-RBD neutralizing antibodies BA7208 and BA7125 from mice engineered to produce human antibodies. While BA7125 showed broadly neutralizing activity against all variants except the Omicron sublineages, BA7208 was potently neutralizing against all tested SARS-CoV-2 variants (including Omicron BA.1-BA.5) except Mu. By combining BA7208 and BA7125 through the knobs-into-holes technology, we generated a biparatopic antibody BA7208/7125 that was able to neutralize all tested circulating SARS-CoV-2 variants. Cryo-electron microscopy structure of these broad-spectrum antibodies in complex with trimeric Delta and Omicron spike indicated that the contact residues are highly conserved and had minimal interactions with mutational residues in RBD of current variants. In addition, we showed that administration of BA7208/7125 via the intraperitoneal, intranasal, or aerosol inhalation route showed potent therapeutic efficacy against Omicron BA.1 and BA.2 in hACE2-transgenic and wild-type mice and, separately, effective prophylaxis. BA7208/7125 thus has the potential to be an effective candidate as an intervention against COVID-19.

学科与关键词

关键词
MOUSEHUMANIZATIONIPILIMUMAB
相关
加载中…
  • A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
    Yuan, Mengqi; Chen, Xiangyu; Zhu, Yanzhi; Dong, Xiaoqing; Liu, Yan; Qian, Zhaohui*; Ye, Lilin*; Liu, Pinghuang*Journal of Virology, 2022, 96(16).被引 6
  • Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants
    Wang, Yanqun; Yan, An; Song, Deyong; Duan, Maoqin; Dong, Chuangchuang; Chen, Jiantao; Jiang, Zihe; Gao, Yuanzhu; Rao, Muding; Feng, Jianxia; Zhang, Zhaoyong; Qi, Ruxi; Ma, Xiaomin; Liu, Hong; Yu, Beibei; Wang, Qiaoping; Zong, Mengqi; Jiao, Jie; Xing, Pingping; Pan, Rongrong; Li, Dan; Xiao, Juxue; Sun, Junbo; Li, Ying; Zhang, Linfeng; Shen, Zhenduo; Sun, Baiping; Zhao, Yanyan; Zhang, Lu; Dai, Jun; Zhao, Jingxian; Wang, Lan*; Dou, Changlin*; Liu, Zheng*Nature Communications, 2024, 15(1): 842.
  • Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
    Wang, Yingdan; Zhang, Xiang; Ma, Yunping; Wang, Yanqun; Zhan, Wuqiang; Zheng, Qinwen; Zhang, Meng; Ji, Ping; Liu, Mei; Liu, Qianying; Sun, Tingting; Zhu, Tongyu; Wen, Yumei; Sun, Lei*; Zhao, Jincun*; Wu, Fan*; Chen, Zhenguo*; Huang, Jinghe*Cell Discovery, 2022, 8(1): 104.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
Cell Discovery
发表日期
2023-01-07
卷期
第 9 卷, 第 1 期
页码
3
DOI
10.1038/s41421-022-00509-9
成果收录
SCIE
资助标注
National Key R&D Program of China [2022YFC0869200, 2021YFC2300101]; National Natural Science Foundation of China [81870246, 82070329, 82172240, 82025001, 32000658]; Guangdong Province International Scientific and Technological Cooperation Projects [2020A0505100063, 2019B1515120068]; ZhongNanShan Medical Foundation of Guangdong Province [ZNSA-2020001, ZNSA-2020013]; State Key Laboratory of Respiratory Disease [SKLRD-Z-202214, SKLRD-Z-202007]; Guangzhou Medical Universty [YP2022005]

作者

  • W

    Wang, Yanqun (第一作者)

    guangzhou med univ · 1

  • Y

    Yan, An

查看全部 41 位作者收起作者
  • S

    Song, Deyong

  • D

    Dong, Chuangchuang

  • R

    Rao, Muding

  • G

    Gao, Yuanzhu

  • Q

    Qi, Ruxi

  • M

    Ma, Xiaomin

  • W

    Wang, Qiaoping

  • X

    Xu, Hongguang

  • L

    Liu, Hong

  • H

    Han, Jing

  • D

    Duan, Maoqin

  • L

    Liu, Shuo

  • Y

    Yu, Xiaoping

  • Z

    Zong, Mengqi

  • F

    Feng, Jianxia

  • J

    Jiao, Jie

  • Z

    Zhang, Huimin

  • L

    Li, Min

  • Y

    Yu, Beibei

  • W

    Wang, Yanxia

  • M

    Meng, Fanhao

  • N

    Ni, Xiaodan

  • L

    Li, Ying

  • S

    Shen, Zhenduo

  • S

    Sun, Baiping

  • S

    Shao, Xin

  • Z

    Zhao, Haifeng

  • Z

    Zhao, Yanyan

  • L

    Li, Rui

  • Z

    Zhang, Yanan

  • D

    Du, Guangying

  • L

    Lu, Jun

  • Y

    You, Chunna

  • J

    Jiang, Hua

  • Z

    Zhang, Lu

  • W

    Wang, Lan (通讯)

  • D

    Dou, Changlin (通讯)

  • L

    Liu, Zheng (通讯)

  • Z

    Zhao, Jincun (通讯)

    shanghaitech univ · 1 · guangzhou med univ · 2

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417